Combining study drug with radiation for early throat cancer
Part of Cancer, Infections clinical trials.
This study tests a new drug (ATRN-119) combined with focused radiation before surgery for people with early-stage HPV-positive throat cancer. It aims to see if this combination can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with HPV-positive throat cancer at an early stage (stage I or II).
- Your overall health is good enough, based on blood tests for calcium, kidney, and liver function.
- You are not pregnant or breastfeeding, and you agree to use effective birth control if applicable.
- You have not had major surgery within 7 days before starting the study drug, and you are not taking certain medications that interact with the study drug.
- You do not have another active cancer, uncontrolled infections, or serious medical conditions that would make the study unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs and a vaccine before standard radiation for HPV-positive throat cancer. It aims to use a less intense radiation dose, which may reduce side effects while still being effective.
This trial tests whether giving lower doses of radiation to certain parts of the throat can be just as effective as standard doses, while reducing side effects. It is for people with HPV-positive throat cancer, which tends to respond well to treatment.
This trial tests whether using a de-escalated (lower/intensity-reduced) radiation approach can treat HPV-positive oropharyngeal squamous cell carcinoma. It may help reduce side effects while still keeping the cancer under control.
This trial tests a less intense treatment plan for HPV-positive throat cancer that is caught early or moderately advanced. The goal is to keep the cancer from coming back while reducing side effects from standard therapy.
This study checks a blood test that looks for HPV tumor DNA to help doctors decide when to start routine treatment after surgery. It may help some people avoid starting treatment too early or too late based on how the test changes after the operation.
This trial tests a lower dose of radiation to certain neck areas for people with HPV-related oropharyngeal cancer. The goal is to see if reducing radiation can cause fewer side effects while still curing the cancer.
Hear when a new HPV Positive Oropharyngeal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.